KB-1294

AMG103-CD19-hIgG1

45445

Home » Antibodies » AMG103-CD19-hIgG1

Background of AMG103-CD19-hIgG1

CD19 is a transmembrane glycoprotein specific to B-lineage cells, with expression maintained in over 95% of B-cell malignancies. This strict lineage specificity positions CD19 as an ideal target for immunotherapies utilizing chimeric antigen receptors (CARs). One notable therapeutic approach is the CD19/CD3 bispecific T-cell engager (BiTE) antibody construct blinatumomab (AMG 103), a synthetic fusion molecule designed to facilitate direct interactions between T-cells and antigen-expressing cells. Blinatumomab has become a standard treatment for relapsed B-cell malignancies, and similar BiTE therapeutics are showing potential in treating various other cancers.

Specifications

Catalog Number	KB-1294
Antibody Name	AMG103-CD19-hIgG1
Isotype	Human IgG1,kappa
Target	CD19
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014 Mar-Apr;20(2):112-8.
Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy. Int Immunol. 2015 Jan;27(1):31-7.
Shepherd A, Bennychen B, Marcil A, et al. A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies. PLoS One. 2023 Jun 22;18(6):e0273884.